Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuraceq PET/MRI in Cardiac Amyloidosis
NCT03119558Phase 1Completed
- Sponsor
- Stanford University
- Start
- May 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flutemetamol in cardiac amyloidosis, sponsored by Stanford University. Primary endpoint: Number of participants with 18F-Florbetaben uptake on Fused PET/MRI Images at 2 hours. Started May 2016; status: completed.
02
Drugs
flutemetamol
03
Conditions
cardiac amyloidosis
Beyond the preview
Go deeper on NCT03119558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03119558.